Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy  by Wizemann, Volker et al.
Atrial fibrillation in hemodialysis patients: clinical
features and associations with anticoagulant therapy
Volker Wizemann1, Lin Tong2, Sudtida Satayathum2, Alex Disney3, Takashi Akiba4, Rachel B. Fissell5,
Peter G. Kerr6, Eric W. Young7,8 and Bruce M. Robinson2,7
1Georg Haas Dialysezentrum, Giessen, Germany; 2Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA; 3Renal Unit,
Queen Elizabeth Hospital, Woodville, South Australia; 4Tokyo Women’s Medical University, Tokyo, Japan; 5Cleveland Clinic, Cleveland,
Ohio, USA; 6Monash Medical Centre, Melbourne, Victoria, Australia; 7University of Michigan, Ann Arbor, Michigan, USA and 8Veterans
Administration Medical Center, Ann Arbor, Michigan, USA
Using data from the international Dialysis Outcomes and
Practice Patterns Study (DOPPS), we determined incidence,
prevalence, and outcomes among hemodialysis patients with
atrial fibrillation. Cox proportional hazards models, to identify
associations with newly diagnosed atrial fibrillation and
clinical outcomes, were stratified by country and study phase
and adjusted for descriptive characteristics and
comorbidities. Of 17,513 randomly sampled patients, 2188
had preexisting atrial fibrillation, with wide variation in
prevalence across countries. Advanced age, non-black race,
higher facility mean dialysate calcium, prosthetic heart
valves, and valvular heart disease were associated with
higher risk of new atrial fibrillation. Atrial fibrillation at study
enrollment was positively associated with all-cause mortality
and stroke. The CHADS2 score identified approximately
equal-size groups of hemodialysis patients with atrial
fibrillation with low (less than 2) and higher risk (more than
4) for subsequent strokes on a per 100 patient-year basis.
Among patients with atrial fibrillation, warfarin use was
associated with a significantly higher stroke risk, particularly
in those over 75 years of age. Our study shows that atrial
fibrillation is common and associated with elevated risk of
adverse clinical outcomes, and this risk is even higher among
elderly patients prescribed warfarin. The effectiveness and
safety of warfarin in hemodialysis patients require additional
investigation.
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Atrial fibrillation (AF) is the most common cardiac
dysrhythmia requiring clinical attention and is associated
with age and cardiovascular morbidity.1 In the general
population, AF is a potent risk factor for stroke (cerebrovas-
cular events)2 and death.3 AF is often associated with
impaired cardiac performance and lower quality of life.4
Given the aging populations and associated rising burden of
cardiovascular disease in industrialized countries, the pre-
valence of AF is expected to increase by 2.5-fold over the next
five decades.5
Decreased glomerular filtration rate and chronic kidney
disease are independently associated with cardiovascular
events.6 Older patients with end-stage renal disease (ESRD)
are a rapidly growing group; the incidence of ESRD has
tripled in the last decade.7 Cardiovascular prognosis is even
worse in patients with coexisting cardiovascular disease and
ESRD requiring hemodialysis (HD) therapy.8 In addition to
these patient-based factors associated with AF, the specific
pattern of intermittent HD may raise the risk of HD patients
developing AF. Differences in the incidence of AF between
HD and peritoneal dialysis patients9 and the occurrence of
supraventricular arrhythmias in the last hours of HD10 point
toward an association between HD practice patterns and the
development of AF in HD patients.
In the general population, clinical trial data support the
use of warfarin for stroke prevention in many patients with
non-rheumatic AF; risk stratification according to stroke risk
(for example, by the CHADS2 score) now guides recom-
mendations for warfarin use.11–13 Though warfarin use in
dialysis patients with AF is common, there are few, if any,
data supporting its efficacy and there are widespread
concerns about its safety.14–16 In the absence of clinical trial
data in dialysis patients, evaluation of tools such as the
CHADS2 score may provide a useful step toward informed
decisions about warfarin use.
This study reports several findings: the prevalence of AF in
an international, representative sample of HD patients; the
associations of AF with comorbid conditions, laboratory
measures, and cardiovascular medications; and the relative
risks of adverse outcomes including mortality and strokes
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among AF patients. An additional goal of this study was to
evaluate the association of anticoagulation therapy with
subsequent strokes and to assess the performance of the
CHADS2 stroke risk stratification scheme as a means to
potentially guide warfarin therapy in HD patients.
RESULTS
Prevalence and incidence of atrial fibrillation
Among the prevalent cross-section of HD patients in the
Dialysis Outcomes and Practice Patterns Study (DOPPS),
12.5% (2188 out of 17,513) had pre-existing AF at baseline
(range 5.6% in Japan to 24.7% in Belgium, see Table 1). The
incidence of newly diagnosed AF during the follow-up period
was 1.0 per 100 patient-years (range 0.5 in Japan to 3.0 in
Sweden). The prevalence of AF increased with age and was
much higher in all age categories than in the general
population (Figure 1).
Associations with pre-existing atrial fibrillation
The baseline cross-sectional model showed a substantially
higher adjusted odds ratio (OR) of pre-existing AF (that is,
with having a known history of AF) with older age (Table 2).
There was no significant difference by sex. However, AF was
less common in black vs non-black patients. The OR of
having AF was higher with more years of HD therapy. AF was
associated with many cardiac conditions (listed in Table 2).
Patients with cerebrovascular disease were marginally more
likely to have AF. AF was significantly associated with left
ventricular hypertrophy, though not with a diagnosis of
hypertension; patients with higher pre-dialysis systolic blood
pressure at the time of study enrollment were less likely to
have AF. Dividing systolic blood pressure into categories,
only the lowest quintile of the systolic blood pressure
(o130mmHg) was associated with pre-existing AF
(OR¼ 1.37, 95% CI¼ 1.18–1.58, Po0.0001) compared with
the reference category of 143–156mmHg.
Associations with newly diagnosed atrial fibrillation
In the longitudinal model evaluating time from enrollment to
hospitalization for new AF (patients with previous AF were
excluded from the analysis) (Table 2), the likelihood of
developing AF was positively associated with older age,
Table 1 | Prevalence and incidence of atrial fibrillation by country
Prevalent (pre-existing) AFa Incident (newly diagnosed) AFb
Country
Total number
of patients
Prevalence
n (%)
OR (95% CI;
P-value)
Incident
cases - n
Incidence per 100
patient-years HR (95% CI, P-value)
Belgium 534 132 (24.7) 1.96 (1.39–2.75; Po0.01) 27 2.9 2.26 (1.25–4.06; Po0.01)
France 1043 191 (18.3) 1.65 (1.27–2.15; Po0.01) 27 1.4 1.41 (0.89–2.22; P=0.14)
Germany 1064 170 (16.0) 1.62 (1.27–2.07; Po0.01) 25 1.2 1.18 (0.71–1.95; P=0.53)
Italy 1137 128 (11.3) 1.09 (0.81–1.46; P=0.57) 40 1.8 1.70 (1.01–2.86; P=0.05)
Spain 1097 163 (14.9) 1.36 (1.01–1.83; P=0.04) 30 1.4 1.38 (0.80–2.36; P=0.25)
Sweden 535 115 (21.5) 2.04 (1.44–2.89; Po0.01) 29 3.0 2.70 (1.54–4.74; Po0.01)
United Kingdom 1041 122 (11.7) 1.20 (0.87–1.64; P=0.26) 18 1.1 1.17 (0.64–2.11; P=0.61)
EUR Overall 6451 1021 (15.8) 1.47 (1.23–1.75; Po0.01) 196 1.6 1.51 (1.09–2.09; P=0.01)
Australia/New Zealand 507 81 (16.0) 1.29 (0.88–1.89; P=0.20) 14 1.6 1.54 (0.63–3.74; P=0.34)
Canada 596 113 (19.0) 1.45 (1.00–2.12; P=0.05) 16 1.6 1.45 (0.79–2.68; P=0.23)
Japan 3935 219 (5.6) 0.67 (0.52–0.87; Po0.01) 36 0.5 0.60 (0.38–0.96; P=0.03)
United States 6024 754 (12.5) 1.00 (Ref.) 125 0.7 1.00 (Ref.)
Overall 17,513 2188 (12.5) — 387 1.0 —
Combined DOPPS I/II data (1996–2004); logistic and Cox models were adjusted for country, phase, age, sex, black race, time with ESRD, CAD, cancer, cerebrovascular disease,
heart failure, diabetes mellitus, GI bleed, HIV/AIDS, hypertension, lung disease, neurological disorder, psychiatric disorder, PVD, and recurrent cellulitis, controlling additionally
for effects of facility clustering. France, Germany, Italy, Japan, Spain, UK, and US participated in both DOPPS I and II. Australia/New Zealand, Belgium, Canada, and Sweden
were only in DOPPS II.
Abbreviations: CAD, coronary artery disease; DOPPS, Dialysis Outcomes and Practice Patterns Study; ESRD, end-stage renal disease; GI, gastrointestinal, PVD, peripheral
vascular disease.
aPrevalent (pre-existing) atrial fibrillation (AF) calculated among baseline DOPPS I and II prevalent cross-sections (n=17,513); OR = adjusted odds ratio of having history of AF
(yes vs no) before study entry.
bIncident (newly diagnosed) AF calculated at follow-up and includes data from all DOPPS I and II patients without a baseline diagnosis of AF (n=25,709); HR = hazard ratio of
hospitalization for new AF during study follow-up (n=387 events overall).
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Figure 1 |Prevalence of history of atrial fibrillation (AF) at
DOPPS enrollment by region and age in prevalent cross-
sections combining DOPPS I (1996–2001) and DOPPS II
(2002–2004) (n¼ 17,513). For comparison, the approximate
prevalence of AF in the same age categories among 1.89 million
adults in the US general population in 1996–1997 is also
shown (ref. 5).
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non-black race, and higher facility mean dialysate
calcium. Other cardiac conditions positively associated with
new AF included valvular heart disease and prosthetic heart
valves.
Medication use in patients with atrial fibrillation
As shown in Table 3, aspirin was the most frequently
prescribed cardiac-related medication (31%) in patients with
pre-existing AF. The relatively frequent prescription (23%) in
Table 2 | Associations with pre-existing and newly diagnosed atrial fibrillation
Pre-existing AF Newly diagnosed AF
Characteristics ORa 95% CI P-value HRb 95% CI P-value
Demographics
Age (per 5 years older) 1.25 (1.22–1.28) o0.001 1.19 (1.14–1.24) o0.001
Male (vs female) 1.07 (0.96–1.19) 0.231 0.88 (0.72–1.08) 0.228
Black race (vs non-black) 0.74 (0.59–0.93) 0.009 0.40 (0.25–0.63) o0.001
Time with ESRD (per 1 year) 1.04 (1.03–1.05) o0.001 1.02 (0.99–1.04) 0.153
Body mass index (per 1 kg/m2) 1.01 (1.00–1.02) 0.007 1.01 (0.99–1.03) 0.392
Dialysis and laboratory values
Pre-HD systolic blood pressure (per 10mmHg) 0.94 (0.92–0.96) o0.001 0.99 (0.95–1.04) 0.788
Duration of HD session (per 30min) 1.08 (1.02–1.14) 0.006 1.01 (0.93–1.09) 0.871
spKt/V (per 0.1) 0.99 (0.96–1.01) 0.248 1.03 (0.99–1.07) 0.154
Serum albumin (per 1 g/dl) 0.92 (0.81–1.04) 0.174 0.90 (0.70–1.16) 0.426
Normalized PCR (per 0.1) 1.00 (0.98–1.03) 0.788 1.02 (0.96–1.08) 0.489
Serum calcium (per 1mg/dl) 1.13 (1.06–1.20) o0.001 0.95 (0.83–1.09) 0.499
Serum phosphorus (per 1mg/dl) 1.02 (0.99–1.06) 0.129 1.05 (0.99–1.11) 0.090
Serum PTH (per 100 pg/ml) 1.00 (0.99–1.02) 0.627 1.03 (0.99–1.07) 0.109
Serum potassium (per 1mg/dl) 0.94 (0.88–1.01) 0.080 0.96 (0.84–1.09) 0.538
Hemoglobin (per 1 g/dl) 0.99 (0.96–1.03) 0.749 0.95 (0.88–1.02) 0.172
Dialysate calcium (per 1 mEq/l) 1.04 (0.87–1.23) 0.678 1.32 (0.96–1.81) 0.082
Dialysate potassium (per 1 mEq/l) 1.18 (1.06–1.31) 0.003 1.03 (0.84–1.27) 0.787
Facility mean dialysate calcium (per 1 mEq/l)c 1.01 (0.76–1.33) 0.955 1.63 (1.04–2.55) 0.034
Facility mean dialysate potassium (per 1 mEq/l)c 1.10 (0.86–1.40) 0.436 0.80 (0.55–1.14) 0.554
Summary comorbid conditions (yes vs no)
Coronary artery disease 1.56 (1.39–1.75) o0.001 1.12 (0.89–1.41) 0.341
Heart failure 2.08 (1.84–2.35) o0.001 1.14 (0.90–1.45) 0.283
Cerebrovascular disease 1.11 (0.98–1.25) 0.090 0.87 (0.65–1.18) 0.374
Hypertension 1.08 (0.95–1.23) 0.232 1.19 (0.89–1.58) 0.239
Peripheral vascular disease 1.02 (0.90–1.16) 0.762 1.03 (0.80–1.34) 0.805
Recurrent cellulitis 1.23 (1.04–1.46) 0.017 1.11 (0.70–1.75) 0.665
Diabetes mellitus 0.89 (0.79–1.00) 0.053 0.88 (0.69–1.13) 0.325
GI bleed 1.18 (0.97–1.44) 0.094 0.97 (0.64–1.46) 0.875
Lung disease 1.15 (1.00–1.32) 0.050 1.15 (0.84–1.56) 0.392
Neurological disorder 1.09 (0.93–1.27) 0.281 1.00 (0.68–1.46) 0.997
Psychiatric disorder 1.15 (1.01–1.30) 0.031 1.07 (0.82–1.39) 0.602
Cancer, other than skin 0.96 (0.83–1.11) 0.585 1.09 (0.81–1.45) 0.575
HIV/AIDS 0.70 (0.26–1.88) 0.484 No events
Other cardiac conditions (yes vs no)
Permanent pacemaker implanted 2.36 (1.90–2.92) o0.001 0.97 (0.49–1.92) 0.921
Left ventricular hypertrophy 1.24 (1.11–1.40) o0.001 1.13 (0.87–1.46) 0.353
Valvular heart disease 1.65 (1.45–1.89) o0.001 1.44 (1.08–1.93) 0.012
History of cardiac arrest 2.22 (1.72–2.87) o0.001 0.73 (0.30–1.80) 0.497
Pericarditis 1.61 (1.25–2.07) o0.001 0.93 (0.52–1.65) 0.799
Prosthetic heart valve 1.71 (1.27–2.32) o0.001 1.94 (1.08–3.50) 0.028
Current medications (Rx vs no Rx)d
Aspirin 0.95 (0.84–1.08) 0.414 1.06 (0.83–1.35) 0.654
Warfarin 2.76 (2.30–3.30) o0.001 0.89 (0.51–1.56) 0.692
b-blocking agents 1.08 (0.96–1.22) 0.188 1.11 (0.85–1.46) 0.448
Digoxin 4.48 (3.80–5.27) o0.001 1.67 (1.08–2.57) 0.020
Angiotensin–converting enzyme inhibitors 0.90 (0.79–1.03) 0.117 1.10 (0.87–1.39) 0.442
Ca channel-blocking agents 1.65 (1.38–1.97) o0.001 1.25 (0.87–1.80) 0.229
Abbreviation: HD, hemodialysis.
aCombined DOPPS I and II data (1996–2004), among respective phase-specific prevalent cross-sections (n=17,513 overall); OR =Adjusted odds ratio of history of atrial
fibrillation (AF) (n=2,188); multivariable model adjusted for all covariates listed (except as below) and country, and controlling for effects of facility clustering.
bCombined DOPPS I and II data (1996–2004), among all patients without a baseline diagnosis of AF (n=25,709 overall); HR = adjusted hazard ratio of hospitalization for new AF
(n=387 events); multivariate model adjusted for all covariates listed (except as below) in addition to phase and country, and controlling for effects of facility clustering.
cFacility dialysate variables were run in separate multivariable models from the patient-level dialysate variables.
dMedications were each run individually in separate multivariable models.
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patients without a history of dysrhythmia indicates that the
proportion of aspirin prescription for specific anticoagula-
tion effects in AF is small. Though prescribed less frequently
than aspirin, prescription of warfarin (16%) was three times
more frequent in patients with pre-existing AF than those
without AF. There was an 18-fold difference between
countries in the frequency of prescribing warfarin to AF
patients, with the lowest usage in Germany (2%) and the
highest in Canada (37%). The overall prevalence of
medications used for AF frequency control among patients
with pre-existing AF was 22% for digoxin, 27% for beta-
blockers, 21% for ACE inhibitors, and 11% for calcium
channel blockers. Use of anti-arrhythmic agents among AF
patients was 15% overall for amiodarone and p1.1% for
other agents. Digoxin was more frequently prescribed to
patients with (vs without) pre-existing AF in all countries, as
were amiodarone and calcium channel-blocking agents in
most countries. Use of amiodarone in AF was extremely
variable among countries: in France nearly 50% were treated
with this Class 3 anti-arrhythmic, but its use in Japan and
Sweden was nearly absent. Beta-blocker and ACE inhibitor
use did not substantially vary by AF status in most countries.
In keeping with the findings in Table 3, prescription
of warfarin (OR¼ 2.76, Po0.001), digoxin (OR¼ 4.48,
Po0.001), and calcium channel-blocking agents (OR¼
1.65, Po0.001) were significantly associated with pre-
existing AF in multivariable models (Table 2).
Mortality and hospitalization
Pre-existing AF at DOPPS enrollment was positively
associated with all-cause mortality (HR¼ 1.16, 95%
CI¼ 1.08–1.25, Po0.001) and hospitalization or death
because of a stroke/cerebrovascular event (HR¼ 1.28, 95%
CI¼ 1.01–1.63; P¼ 0.048) after adjusting for sex, black race,
years of ESRD, age, 14 summary comorbidities, and
excluding patients with a prosthetic heart valve. Pre-existing
AF was also positively associated with cardiac mortality
(HR¼ 1.10, 95% CI¼ 0.98–1.23; P¼ 0.09) whereas no
association was observed with all-cause hospitalization
(HR¼ 1.02, 95% CI¼ 0.96–1.07; P¼ 0.59).
Compared with patients without AF at DOPPS enroll-
ment, those with AF had a significantly higher rate of
subsequent stroke/cerebrovascular events (hospitalization or
death because of cerebrovascular causes) during follow-up
(3.4 vs 1.9 events per 100 patient-years; adjusted HR¼ 1.28,
95% CI¼ 1.01–1.62 for AF vs no AF, P¼ 0.048).
Stroke risk stratification
To evaluate the performance of CHADS2 as a stroke risk
stratification score to potentially guide anticoagulation
decisions, stroke rates according to CHADS2 score for
patients with AF at DOPPS enrollment are provided in
Table 4. Patients with a prosthetic heart valve (n¼ 177) were
excluded, as use of warfarin is required in these patients.
Findings are presented for all other AF patients (n¼ 3250), as
well as restricted to AF patients (n¼ 643) without valvular
heart disease and taking acetylsalicylic acid (ASA, aspirin) but
not warfarin (as used for CHADS2 development).13 The table
shows that the cerebrovascular event rate for patients with
CHADS2¼ 0 was o1 per 100 patient-years, and that the
event rate increased monotonically with rising CHADS2
scores (to 12–19 per 100 patient-years at the maximum
CHADS2 score). In a multivariable model, three of the five
CHADS2 variables (history of previous stroke, diabetes, and
older age) were significantly associated with subsequent
stroke, but the other two (hypertension and heart failure)
were not (data not shown).
Warfarin use and stroke risk
As shown in Figure 2, warfarin use among patients with pre-
existing AF was associated with elevated stroke risk in older
patients, with HR¼ 1.29 (95% CI¼ 0.45–3.68; P¼ 0.63) for
patients p65 years, 1.35 (95% CI¼ 0.69–2.63; P¼ 0.39) for
patients 66–75 years, and 2.17 (95% CI¼ 1.04–4.53, P¼ 0.04)
Table 3 |Medication use among patients according to atrial fibrillation status, by region
Medication (% use)
Aspirin Warfarin
b-Blocking
agents
Calcium channel-
blocking agents ACE inhibitors Digoxin Amiodarone
Country/region AF No AF AF No AF AF No AF AF No AF AF No AF AF No AF AF No AF
Belgium 33 31 7 3 31 30 2 2 19 23 3 2 25 3
France 27 20 5 1 18 21 9 6 20 20 11 1 46 6
Germany 37 31 2 2 34 34 12 8 37 30 4 0 7 1
Italy 24 21 14 5 7 9 7 5 13 16 24 6 29 2
Spain 25 17 4 0 11 13 9 4 15 14 25 2 22 2
Sweden 39 36 16 3 57 51 3 2 15 18 21 2 2 0
United Kingdom 46 35 24 11 31 23 2 4 21 24 21 2 22 1
EUR Overall 32 26 9 4 26 23 7 5 21 20 15 2 23 2
Australia/New Zealand 33 41 25 4 26 26 12 9 22 28 27 3 14 2
Canada 40 38 37 17 42 47 8 8 28 39 18 2 9 2
Japan 17 10 5 1 13 9 14 8 13 18 17 3 0 0
United States 30 25 26 8 31 30 17 9 22 24 33 8 8 1
Overall 31 23 16 5 27 23 11 7 21 22 22 4 15 1
Combined DOPPS I/II data (1996–2004); among baseline DOPPS I and II prevalent cross-sections (n=17,220). Patients with AF had ‘history of atrial fibrillation’ at DOPPS
enrollment.
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for patients 475 years. Warfarin use (compared with non-
use) was also associated with elevated stroke risk in patients
with high (X3) but not lower CHADS2 scores. However, this
finding was explained by age (Figure 2), not the other
CHADS2 variables. AF was not associated with elevated risk
of hospitalization because of gastrointestinal bleeding, and
this relationship was not influenced by the use of aspirin,
warfarin, or other anticoagulation medications (data not
shown).
DISCUSSION
Epidemiology of atrial fibrillation
This international study confirms that AF is common in the
HD population, with prevalence several times higher than in
the general population.2,5 In support of our findings, the
prevalence of AF among HD patients in previous smaller
studies was 14 to 27%,17–22 and the incidence of AF in the
US-DOPPS population was almost identical to that reported
in the United States Renal Data System for a cohort of
dialysis patients hospitalized for AF.9
There was a more than threefold variation in reported
AF between DOPPS countries (Table 1). This may represent,
in part, differences in the detection of AF between countries.
The DOPPS medical questionnaire asks if the patient has
a history of AF (yes or no), but does not require ECG
documentation. On the other hand, the much lower
prevalence of AF in Japan than in other countries may be
largely due to true differences in prevalence. This possibility
is consistent with the lower prevalence of cerebrovascular
disease in Japanese HD patients than elsewhere.23,24
Atrial fibrillation and associated conditions
As in the general population,5,25 the incidence and prevalence
of AF in the HD population was higher in older patients and
in non-black compared with black patients (Table 2 and
Figure 1). Greater duration of ESRD was also associated
with higher incidence and prevalence of AF. Numerous
cardiovascular conditions were associated with pre-existing
AF, which is very comparable with associations observed
in the general population1,3,25 and described for dialysis
patients in Italy, Turkey, New Zealand, Spain, and the United
States.9,18–20,22
Table 4 | Stroke rates among HD patients with history of atrial fibrillation, by CHADS2 scorea
(A) Patients with history of non-valvular
AF—prescribed aspirin but not warfarinb
(B) All patients with history
of non-valvular AFb
CHADS2
scorec
Patients
(n)
Stroke
events (n)
Stroke rate per 100
patient-yearsd
Patients
(n)
Stroke
events (n)
Stroke rate per 100
patient-yearsd
0 16 0 0.0 141 1 0.5
1 114 1 0.6 568 18 2.1
2 174 6 2.3 875 23 1.9
3 167 8 3.8 882 45 3.9
4 92 6 5.6 403 27 6.0
5 70 6 6.1 311 25 6.5
6 10 2 19.0 70 9 12.7
Overall 643 29 3.3 3250 148 3.4
aStroke rates during DOPPS follow-up among patients with history of atrial fibrillation (AF) at DOPPS enrollment, excluding 177 patients with mechanical heart valves.
bColumn A includes dialysis patients generally comparable with those used to evaluate CHADS2 in the general population; 27 patients on heparin between dialysis sessions
but not warfarin were also excluded; column B includes all AF patients without a mechanical heart valve.
cBased on stroke risk according to CHADS2 score in the general population: 0=low, 1 or 1–2=moderate, and X2 or 3=high risk. Among a non-dialysis Medicare population
with non-valvular AF and not receiving warfarin, stroke rates for CHADS2 score=0, 1–2, and X3 were 0.8, 2.7, and 5.3 per 100 patient-years, respectively (refs. 11–13).
dColumn A=891 patient-years; column B=4348 patient-years.
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Figure 2 |Hazard ratio (HR) for stroke according to warfarin
use, by age categories among patients with a diagnosis of
atrial fibrillation at DOPPS enrollment. The numbers of patients
(strokes) were 1001 (35), 1137 (61), and 1107 (49) for age groups
p65, 66 to 75, and 475 years, respectively. The numbers (%) of
patients on warfarin were 146 (15%), 192 (17%), and 171 (15%) for
age groups p65, 66 to 75, and 475 years, respectively. Patients
with prosthetic heart valves (N¼ 177) were excluded. Separate
Cox models for each age category were used to estimate the
hazard ratio and 95% confidence interval (whiskers) of first stroke
after study entry, adjusted for age within the restricted category,
sex, black race, years with ESRD, study phase, history of stroke,
comorbid conditions as listed in Table 2, permanent pacemaker
implanted, previous history of cardiac arrest, left ventricular
hypertrophy, and valvular heart disease, stratified by region and
study phase and accounting for effects of facility clustering. In
addition to warfarin use, the following variables were statistically
significant (Po0.05) in a model including all age categories:
neurologic disease (P¼ 0.02), diabetes (P¼ 0.03), and previous
history of stroke (P¼ 0.002).
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The association between pre-existing AF and lower
blood pressures (Table 2) is also notable. Dividing
systolic blood pressure (SBP) into categories, only the lowest
quintile of the SBP range (o130 mmHg) was
associated with pre-existing AF (HR¼ 1.37, 95%
CI¼ 1.18–1.58, Po0.0001). The longitudinal model
of the occurrence of new AF detected no such
associations with low blood pressure. Taken together, these
data are consistent with the possibility that low blood
pressure is a sequela, not a cause, of AF and/or associated
comorbidities.
Many other cardiac conditions studied (heart failure,
valvular heart disease, permanent pacemaker, and others)
were associated with pre-existing AF, as expected (Table 2). In
contrast to the associations with pre-existing AF, only
valvular heart disease and prosthetic heart valves were
associated with newly diagnosed AF. In addition, patients
using digoxin were more likely to develop AF, probably
because cardiovascular abnormalities that are indications for
digoxin therapy also raise the risk of developing AF. The
absence of anticipated associations of some cardiac condi-
tions with new AF may be due to the relatively rare
occurrence, or reporting, of new AF. Reports have shown
that progression of renal failure and time on ESRD therapy
are associated with multiple cardiovascular alterations,
such as the easily detectable progression of left ventricular
hypertrophy and cardiac atrial diameters;26,27 overt or
masked calcifications of cardiac valves, myocardium, and
media of vessels;28–30 and the progressive increase in cardiac
fibrosis.31,32 Many of these alterations escape clinical
detection (and therefore are not captured in the DOPPS)
despite the fact that left atrial enlargement—which is
prevalent in 40% of HD patients27—is a powerful predictor
of AF.33 In a study from northern Italy, which prospectively
followed by ECG 349 hospital-based HD patients over
3 years, 35 had new onset AF, and in a multivariable analysis
there was a significant association with left ventricular
hypertrophy.34
Pharmacological intervention to achieve heart rate
control is a primary therapeutic approach for recurrent
and persistent AF.35–37 In the AFFIRM study,35 digoxin
(71%), b-blockers (47%), and nondihydropyridine calcium
channel antagonists (40%) were commonly used in AF
patients. If these data in cardiac patients are applied as
standards for HD patients with AF, then these three
classes of drugs were underused by a factor of approximately
2.5 in the DOPPS (Table 3). The large international
variability in amiodarone use may be explained by different
opinions about risk-benefit assessment in the absence of
long-term effectiveness, safety, and outcomes data in dialysis
patients. Although the drug is effective in achieving and
maintaining sinus rhythm in non-renal patients with AF,38
concerns about long-term toxicity and interactions with
drugs like statins, digoxin, and warfarin may cause some
providers to be reluctant to prescribe the drug to dialysis
patients.
Atrial fibrillation and clinical events
In the general population, the risk of death or stroke
attributed to AF without overt structural heart disease is low
below the age of 60 years.1,3,39 However, older patients with
AF and arterial hypertension have an increased complication
rate. The possibility that AF in HD patients might be a
marker for other undetected cardiovascular disease is
supported by the independent association of years on dialysis
with AF, as more years on dialysis is generally associated with
increased prevalence of cardiovascular disease.
In previous studies of dialysis patients, overall mortality
was elevated by as much as 1.7–3.8 times among patients with
vs without AF.18,34 In this study, the magnitude of the excess
risk of all-cause mortality in HD patients with AF was smaller
(adjusted HR¼ 1.17, 95% CI¼ 1.08–1.24, Po0.01). Our
findings are generally comparable with the magnitude of the
adjusted HR of mortality from AF (1.31) in long-term
observational studies in the general population.1,3,39 The
relative risk of cardiovascular death in HD patients with AF
was also elevated (adjusted HR¼ 1.16, 95% CI¼ 1.08–1.24,
P¼ 0.009), which underlines the association of AF with
coexisting cardiovascular disease.9,18–20,40
There is an excessive stroke risk in the ESRD population,
and mortality after stroke is very high.41–43 In the general
population, AF is associated with a sixfold increased risk for
stroke,44 with the mechanism considered to be embolism
originating as thrombus in the fibrillating atrial appendage.45
In our study, HD patients with AF had a higher rate of
subsequent stroke than those without AF (3.4 vs 1.9 events
per 100 patient-years; HR¼ 1.79, P¼ 0.003). This difference
is directionally similar to that for AF patients in the general
population, although the magnitude is notably smaller.
Our finding contrasts with some previous smaller studies
of AF among HD patients, which found no elevation of
stroke risk.17,34 However, in another study, the rate of
ischemic stroke was higher in dialysis patients with AF (3 of
40 patients) compared with those without AF (3 of 115
patients).21
Stroke risk and warfarin therapy in AF
Risk-benefit assessment with respect to anticoagulation
therapy for stroke prophylaxis is crucially dependent on the
magnitude of stroke risk, as well as the effectiveness and
safety of anticoagulation therapy.13 With regard to the
former, risk stratification can help guide informed clinical
decision making.46 The CHADS2 score (an acronym for
congestive heart failure, hypertension, age 475 years,
diabetic status, and history of stroke or transient ischemic
attack) was developed to predict the risk of subsequent stroke
(and therefore to help guide anticoagulation therapy) among
patients with AF in the general population.13 CHADS2 has
been adapted in a clinical practice guideline for AF patients,
and it was recently endorsed in the United States as part of
a clinical performance measure for management of
AF.11,12 Using DOPPS data, this study has found that in
dialysis patients CHADS2 effectively identified approximately
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equal-sized patient groups at low and higher risk for
subsequent stroke (rates o2 and 44 per 100 patient-years,
respectively) (Table 4). CHADS2 performance was compar-
able in (A) patients without valvular heart disease and not
prescribed warfarin (as used for CHADS2 validation in the
general population) and (B) for a less restricted group of
patients. Notably, CHADS2 scores were higher in this
study than in the general population (by 0.6 for mean and
1.0 for median), and thus the proportion at higher
risk was somewhat greater.47
The absolute stroke rate among patients in the
low-risk group in our study (o2 per 100 patient-years)
is approximately equal to the rate below which antic-
oagulation is not recommended in the general
population with AF.11–13 In conjunction with data validating
CHADS2 for the identification of low-risk patients in the
general population, these findings may support the decision
to not anticoagulate dialysis patients with AF and a low
CHADS2 score, in the absence of other indications for
anticoagulation.
On the other hand, several CHADS2 components
(hypertension, heart failure) in our dialysis population were
not independently associated with stroke. Hypertension
may not predict stroke in dialysis patients because its
epidemiological associations differ from those in the general
population: most (480% of) HD patients have a history
of hypertension, and patients with high blood pressure
paradoxically survive longer, due in part to better health
status. The explanation for the finding for heart failure is less
evident. Regardless of the reason, our data indicate that
CHADS2 may misclassify some low-risk HD patients as
having higher stroke risk than they actually have. Modifica-
tions to CHADS2 (for example, dropping hypertension and
heart failure) might strengthen its ability to discriminate low
vs higher risk patients. However, these possible modifications
are speculative and require validation in other data sets.
With respect to the effectiveness and safety of anti-
coagulation therapy, the risk of hemorrhagic stroke is
elevated in HD patients.41,42,48,49 Rigorous clinical data
evaluating anticoagulation in dialysis patients are sparse.
However, routine warfarin use has been questioned because it
(1) further increases risk of bleeding and (2) may promote
vascular calcification (by inhibiting vitamin K-dependent
g-carboxylation).15,16,50 In addition, recent observational
data have linked warfarin use to higher mortality rates in
patients with or without AF.14 These observations raise the
important possibility that the strategy of anticoagulation for
AF may not be safe for certain dialysis patients. Underscoring
this possibility is our finding that anticoagulation with
warfarin in HD patients with AF was not associated with the
desired effect—fewer cerebrovascular events. In contrast,
there was a strong tendency to more frequent events,
especially among older patients (Figure 2). Although this
observation may be confounded (patients receive warfarin
because they have elevated risk of thromboembolic stroke) or
causal (anticoagulation leads to elevated rates of hemorrhagic
stroke) or both, the finding underscores the need for caution
when prescribing anticoagulation to these patients.
In summary, CHADS2 appears to effectively identify
groups of dialysis patients with AF who are at low risk for
subsequent stroke, though it may misclassify some patients
(for example, those with hypertension or heart failure) as
having higher stroke risk than they actually have. For patients
identified by CHADS2 as having low stroke risk, this provides
further evidence against anticoagulation therapy. For some
patients at higher stroke risk (especially older patients), the
risks of anticoagulation may still outweigh the benefits.
Treatment decisions need to be individualized, and further
studies including randomized trials of anticoagulation
therapy (possibly including future factor Xa antagonists) in
dialysis patients are needed.
Limitations of the study
Though this is the largest international study, to date, to
describe AF and anticoagulation in AF patients among HD
patients, there are several limitations. First, as in any
observational study, the associations found may not be
causal, and the possibility of bias due to unmeasured
confounding cannot be excluded. Second, DOPPS question-
naires do not distinguish ischemic from hemorrhagic stroke.
As noted above, the excess stroke risk for patients receiving
warfarin may be due to an excess of ischemic and/or
hemorrhagic stroke. As a corollary, INR data are not available
in the DOPPS, and thus neither inadequate nor excessive
anticoagulation among warfarin-treated patients can be
excluded. As patients on warfarin often receive the same
dose of heparin during dialysis as patients not receiving
warfarin, excessive anticoagulation, even if transient, might
constitute a possibly modifiable risk.
Third, because the DOPPS relies exclusively on data
collection by questionnaires, misclassification of AF is likely,
as ECG confirmation is not obligatory and some AF may
escape clinical detection. In occasional cases, patients with
transient (for example, post-operative) AF might be classified
as having AF, even though anticoagulation decisions may
be unnecessary in these patients. DOPPS data also do not
differentiate between paroxysmal, persistent, or permanent
AF. Current guidelines for AF patients in the general
population recommend that some management decisions
(for example, selection of antithrombotic therapy) be
irrespective of AF type, whereas others (for example, rate vs
rhythm control) depend in part on AF type.12 Some
misclassification of valvular heart disease (yes/no) is prob-
able, and the DOPPS does not differentiate between location
of (for example, mitral vs aortic) valvular disease. However,
these limitations are unlikely to substantially influence our
findings with respect to the predictive value of CHADS2
because performance was similar in patients with and
without diagnosed valvular heart disease (Table 4). Patients
with a prosthetic heart valve are identified in the DOPPS, and
these patients were appropriately excluded from the analyses
of CHADS2 as a predictive tool.
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CONCLUSIONS
Results of this large, multinational study clearly indicate
wide variations in the diagnosis of AF in different countries
and variations among several factors associated with AF.
New AF is associated with higher age, greater overall time
on dialysis, and coexisting cardiovascular disease. Previous
diagnosis of AF is associated with an elevated risk of
mortality, cardiovascular mortality, stroke, and hospitaliza-
tions. Beta-blockers or calcium antagonists appear to be
underused for rate control. The risks and benefits of
anticoagulation have to be carefully weighed on an individual
basis. To this end, the CHADS2 score can be used to identify
low vs higher stroke risk. Additional clinical studies to
evaluate the safety and efficacy of treatments for dialysis
patients with AF are indicated.
MATERIALS AND METHODS
Data were combined from the first and second phases of the Dialysis
Outcomes and Practice Patterns Study (DOPPS I and DOPPS II,
respectively), an international, observational study of HD practices
and outcomes in countries with large populations of dialysis patients.
The study design has been described previously.51 IRB approval and
informed patient consent were obtained as required in each country.
A representative sample of HD facilities was selected in each country
within DOPPS I and II (countries in both DOPPS I and II are France,
Germany, Italy, Spain, and the United Kingdom, n¼ 40 each; Japan,
n¼ 125; the United States, n¼ 222; countries in DOPPS II only are
Australia/New Zealand, Belgium, Canada, Sweden, n¼ 20 each).
Patients were entered into DOPPS I from 1996 to 2001 in the United
States, from 1998 to 2000 in Europe, and from 1999 to 2000 in Japan.
All patients in DOPPS II were enrolled from 2002 to 2004. A random
sample of patients was selected from each facility at the start of both
phases, representing a prevalent cross-section (n¼ 17,513). The initial
cross-sectional sample of prevalent patients was used to describe
patient characteristics, whereas the entire sample of 29,873 patients
was used for statistical modelling.
Patients were classified as having ‘pre-existing’ (that is, a history
of) AF at DOPPS enrollment based on a response of ‘yes’ or
‘suspected’ AF on the medical questionnaire. Patients who did not
have pre-existing AF at enrollment but were subsequently
hospitalized with the diagnosis ‘atrial fibrillation’ were classified as
developing ‘newly diagnosed’ AF during the study. Patients were
classified as having a cerebrovascular event during the study if they
were hospitalized for stroke or if they died with cause of death listed
as ‘cerebrovascular accident (including intracranial hemorrhage).’
Standard descriptive statistics were used to describe the cross-
sectional sample of patients. For patients with pre-existing AF at
DOPPS enrollment, CHADS2 score (an acronym for congestive
heart failure, hypertension, age 475 years, diabetes mellitus, and
previous stroke or TIA) was calculated as sum of two points for
previous stroke or TIA, and one point for each other factor (range
0–6).13 Multivariable logistic regression models, adjusted for
country, phase, and the variables listed in Table 2 and accounting
for facility-clustering effects, were used to determine the associations
with patients with pre-existing AF. Multivariable cox proportional
hazard models were used to study associations with (1) time to
hospital admissions for newly diagnosed AF, and (2) time to
mortality, stroke, or hospitalizations among patients with AF.
Cox models were stratified by country and phase, adjusted for the
variables listed in Table 2, and accounted for facility-clustering
effects using robust standard estimates based on the sandwich
estimator. Statistical analyses were performed using SAS software,
version 9.1 (SAS Institute; Cary, NC, USA).
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